| Literature DB >> 29728712 |
H M Hoffmeister1, H Darius2, M Buerke3,4.
Abstract
The use of anticoagulants is associated with an increased risk of bleeding and nevertheless bleeding complications can be lifethreatening. The focus is on bleeding under direct oral anticoagulants (DOAC) because antidotes and specific measures are lacking for some DOACs. Furthermore, routinely carried out clotting tests cannot be used to determine the degree of anticoagulation under DOACs. Therefore, it becomes difficult to determine whether the coagulation inhibition effect is present. This article presents the treatment of hemorrhage in patients with DOACs in the intensive care unit. Further, the indications for DOACS and details of administration and monitoring are presented.Entities:
Keywords: Apixaban; Blood coagulation; Blood coagulation factors; Dabigatran; Edoxaban; Hematologic agents; Rivaroxaban
Mesh:
Substances:
Year: 2018 PMID: 29728712 DOI: 10.1007/s00063-018-0436-8
Source DB: PubMed Journal: Med Klin Intensivmed Notfmed ISSN: 2193-6218 Impact factor: 0.840